Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Exact Sciences will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com
Questions? Email: gps@mdxhealth.com
Low-Risk Report
The low-risk report integrates clinical, pathological, and genomic insights into actionable information on active surveillance1
- Predicts tumor aggressiveness to help inform the decision between active surveillance and immediate treatment
- Focuses on an actionable endpoint adverse pathology, with the most comprehensive definition
- The Oncotype DX Genomic Prostate Score® (GPS™) test is the only commercially available test to provide all these endpoints:
- Risk of high-grade (≥Grade Group 3) disease
- Risk of pT3a+ disease
- Risk of metastasis within 10 years
- Risk of PCa-specific death within 10 years
Watch Director of Urologic Oncology Medical Affairs Dr. Daniel Shoskes, MD, discuss what the GPS report offers for low-risk patients.
High-Risk Report
The high-risk report provides a defined cut point with actionable information on treatment intensity2
- Helps determine the right level of treatment
- Clearly stratifies patient risk into lower or higher likelihood of disease progression
- Simple bell curve helps you and your patient understand the patient’s risk relative to other patients of same clinical risk group
Watch Director of Urologic Oncology Medical Affairs Dr. Daniel Shoskes, MD, discuss what the GPS report offers for high-risk patients.
-
References: